Search

everythinglearnresearchcommunity

for

Search:↓

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

PP405 may revive dormant hair follicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

The user is one month into their FUE treatment and has just undergone PRP treatment at American Mane in Miami. They plan to start using minoxidil and LLT, take xpecia with saw palmetto, and try Exosome from ExoScrt and PRP for better hair growth results.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Combining topical finasteride with RU58841 for hair loss treatment. Users discuss the effectiveness and potential side effects of oral and topical finasteride.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The conversation is about finding a high-quality copper peptide powder for long-term hair growth, to be mixed with rosemary oil. It also suggests using finasteride for hair loss treatment.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

Yokohama University and Dr. Fukuda plan human hair multiplication trials in 2023. Users express hope for future hair cloning treatments over current hair transplants.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

A user discusses their experience with dissolving high concentrations of minoxidil in various ethanol/PG ratios and mentions difficulties with combining it with RU58841. They note that a 5% minoxidil solution remains stable, while higher concentrations tend to precipitate.

The user is asking for opinions on whether their hair growth is due to Pantostin and hormone treatments. One commenter confirms regrowth and asks about the hormone treatments.

The conversation is about sourcing RU58841 for hair loss treatment in Australia and discusses the lack of effective alternatives. Alternatives mentioned include Kx826, fluridil, cb, alfatradiol, and topical spiro, but they are considered weak compared to RU58841.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.